title: [Roferon: present and future indications].
authors.affiliation: Institut Gustave-Roussy, Villejuif, France.
authors.forename: M
authors.initials: M
authors.lastname: Ostronoff
authors.forename: E
authors.initials: E
authors.lastname: Zambon
authors.forename: M
authors.initials: M
authors.lastname: Schlumberger
authors.forename: C
authors.initials: C
authors.lastname: Parmentier
authors.forename: M
authors.initials: M
authors.lastname: Hayat
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins
chemical_list: D000970:Antineoplastic Agents; D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins